Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
OSF Healthcare System
NCT06658496 · Patent Ductus Arteriosus, Congenital Heart Disease
NCT07143201 · Patent Ductus Arteriosus, Preterm
NCT06298344 · Congenital Heart Disease, Thiamine Deficiency, and more
NCT06587282 · Patent Ductus Arteriosus (PDA)
NCT03456336 · Infant, Premature, Patent Ductus Arteriosus, and more
Children's Hospital of Illinois at OSF Saint Francis Medical Center
Peoria, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions